Intraoperative parathyroid hormone assay during surgery for secondary hyperparathyroidism: is it time to give up the chase at the hormone?

Miccoli, Paolo
December 2012
Endocrine (1355008X);Dec2012, Vol. 42 Issue 3, p459
Academic Journal
The author discusses the fate of intraoperative parathyroid hormone therapy (PTH) during surgery for secondary hyperparathyroidism. He mentions that the technique failed to determine the cutoff for the PTH drop rate. He adds that limitations of the technique limits can influence the outcomes in patients with secondary HPT (SHPT) and tertiary HPT, where the cutoff is more difficult to determine.


Related Articles

  • Radiofrequency ablation as treatment for chronic venous insufficiency. Rubin, Susan B.; Rubin, Brian G. // JAAPA: Journal of the American Academy of Physician Assistants (;Mar2011, Vol. 24 Issue 3, p44 

    The article offers a review on the use of radiofrequency ablation (RFA) and endovenous laser ablation (EVLA) in treating chronic venous disease in the U.S. It says that laser ablation and RFA of saphenous vein are invasive surgical procedures with superb midterm and early results for patients...

  • Impact of a Phone Follow-Up Program on Persistence with Teriparatide or PTH(1-84) Treatment. Tamone, Cristina; Fonte, Gianfranco; Panico, Anna; Molinatti, Pia; D'Amelio, Patrizia; Isaia, Giovanni // Calcified Tissue International;Apr2012, Vol. 90 Issue 4, p272 

    A follow-up program to help patients suffering from severe osteoporosis during their therapy with teriparatide or PTH(1-84) has been designed and performed. The objective of this study was to evaluate the 18-month persistence on these therapies in patients participating in the program. We...

  • Parathyroid hormone/teriparatide.  // Reactions Weekly;5/1/2010, Issue 1299, p26 

    The article describes the case of a 61-year-old postmenopausal woman who developed normochromic normocytic anaemia after receiving parathyroid hormone and teriparatide.

  • Osteoporosis: Are Two Drugs Better Than One? Kuritzky, Louis // Primary Care Reports;Oct2013 Clinical Briefs, p20 

    The article focuses on the study conducted by J. N. Tsai and colleagues, which discusses the treatment of osteoporosis by combining the agents teriparatide (TERI) and denosumab (DENO).

  • Åžiddetli Postmenopozal Osteoporozlu Hastalarda Teriparatid Tedavisinin AÄŸrı, YaÅŸam Kalitesi, Depresyon ve Biyokimyasal Parametreler üzerine Etkisi: Erken Dönem Sonuçlar. AKYOL, Yeşim; ATMACA, Ayşegül; DURMUŞ, Dilek; ULUS, Yasemin; TANDER, Berna; ALAYLI, Gamze // Turkish Journal of Physical Medicine & Rehabilitation / Turkiye ;Sep2011, Vol. 57 Issue 3, p134 

    Objective: The aim of this trial was to determine the early effects of teriparatide treatment on back pain, quality of life, depression, and biochemical parameters in patients with severe postmenopausal osteoporosis (OP). Materials and Methods: Twenty-one female patients with severe...

  • Outcomes After Liver Transplant in Patients Aged 70 Years or Older Compared With Those Younger Than 60 Years. Aduen, Javier F.; Sujay, Bangarulingam; Dickson, Rolland C.; Heckman, Michael G.; Hewitt, Winston R.; Stapelfeldt, Wolf H.; Steers, Jeffrey L.; Harnois, Denise M.; Kramer, David J. // Mayo Clinic Proceedings;Nov2009, Vol. 84 Issue 11, p973 

    OBJECTIVE: To compare mortality, graft loss, and postoperative complications after liver transplant in older patients (≥70 years) with those in younger patients (<60 years). PATIENTS AND METHODS: Outcomes for 42 patients aged 70 years or older who underwent liver transplant were compared...

  • New options in treating osteoporosis. LoBuono, Charlotte // Drug Topics;5/5/2003 Supplement, Vol. 147 Issue 9, p9S 

    Focuses on the alternative option in the treatment of osteoporosis called teriparatide, a recombinant form of human parathyroid hormone. Recommended administration; Most common adverse effects; Other therapies for osteoporosis.

  • Teriparatide (hPTH-[1-34]). Ashworth, L.E. // Formulary;Mar2002, Vol. 37 Issue 3, p129 

    Examines the efficacy of teriparatide (hPTH-[1-34]) in treating osteoporosis. Pharmacological properties of teriparatide; Increase in the total-body bone mass density; Adverse effects of the drug.

  • Teriparatide patch deemed safe, effective to increase postmenopausal BMD.  // Endocrine Today;Feb2010, Vol. 8 Issue 2, p25 

    The article discusses research on the safety and effectiveness of teriparatide patch in increasing postmenopausal body mass index (BMD), by C. Cosman and colleagues, published in the 2010 issue of the "Journal of Clinical Endocrinology and Metabolism."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics